A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC).
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Abiraterone acetate
- drug : Prednisone
- drug : Placebo
Phase: Phase 3
Ages Eligible For Study:
- Metastatic castration-resistant prostate cancer (CRPC) - Previous anti-androgen therapy and progression after withdrawal - ECOG performance status of either 0 or 1 - Medical or surgical castration with testosterone less than 50 ng/dL - Life expectancy of at least 6 months